With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

The filmmaker’s candid post opens a conversation about health, stigma, and promising advances in diabetes and weight ...

Baron Fifth Avenue Growth Fund declined during the first quarter of 2025, underperforming its benchmark, the Russell 1000 ...

While drugmakers battle over costs, MoveSmarter Health, a U.S. startup launched in Argentina, is sidestepping the fray with a ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

To help spread the message that managing Type 2 diabetes “doesn’t have to be a solo act,” Eli Lilly, fittingly, is assembling ...

First, he landed his role in "Modern Family," a critically acclaimed ABC sitcom that went on for 11 seasons and catapulted ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Emmy Award-winning actor Eric Stonestreet, known for his portrayal of Cameron Tucker on ABC’s hit sitcom Modern Family, has revealed his private health journey with type 2 diabetes and how medication ...

Q, reporting significant increases in revenue and net income for the three months ended March 31, 2025. Revenue surged to $12 ...